Cyclin-dependent kinase 8 (Cdk8) is a member of the cyclin-dependent kinase (CDK) family, proteins that play vital roles in controlling cell cycle progression and transcriptional regulation. Unlike many of its CDK counterparts that are predominantly involved in the cell cycle, Cdk8 primarily functions in the context of transcription. It is a component of the mediator complex, a multi-protein assembly that bridges the general transcription machinery and gene-specific regulatory proteins. Within this complex, Cdk8, along with its regulatory partner cyclin C, modulates the activity of RNA polymerase II, influencing the transcription of specific gene sets. By doing so, Cdk8 can act as both a positive and negative regulator of transcription, depending on the cellular context and the genes in question. Its role in fine-tuning transcriptional outputs underscores its significance in various cellular processes, ranging from development to stress responses.
Activators of Cdk8 are molecules or compounds that enhance the kinase activity, stability, or expression of Cdk8. These activators might function by promoting the transcription or translation of the Cdk8 gene, stabilizing the protein's conformation, or potentiating its kinase activity either directly or through its association with cyclin C. The presence of Cdk8 activators can have profound implications on transcriptional dynamics, influencing gene expression patterns, cellular responses to environmental cues, or developmental trajectories. Venturing into the domain of Cdk8 activators offers rich insights into the intricate world of transcriptional control and its regulation by CDKs. As the complex tapestry of gene regulation continues to be decoded, the role of Cdk8 and its activators stands as a compelling chapter, elucidating the molecular mechanisms that shape cellular identity, function, and fate.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
A potent CDK inhibitor that targets multiple CDKs, including CDK8. It can arrest cell cycle and induce apoptosis in cancer cells. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
A pan-CDK inhibitor that can inhibit CDK8. It interferes with cell cycle progression and has antitumor properties. | ||||||
MLN 8054 | 869363-13-3 | sc-484828 | 5 mg | $398.00 | ||
Although primarily a CDK1 inhibitor, it might have some activity against CDK8. It can inhibit cell proliferation and induce cell cycle arrest. | ||||||
4-(1H-Pyrazol-4-yl)pyrimidine | 28648-87-5 | sc-256615 sc-256615A | 1 g 5 g | $95.00 $334.00 | ||
A class of compounds known to inhibit CDK8. Their exact mechanism and specificity can vary based on structural modifications. | ||||||
PHA 767491 hydrochloride | 942425-68-5 | sc-204187 sc-204187A | 10 mg 50 mg | $198.00 $802.00 | 3 | |
A dual inhibitor of CDK7 and CDK8. It can arrest the cell cycle and has potential antitumor activity. | ||||||
PD 0332991 Isethionate | 827022-33-3 | sc-478943 | 1 mg | $300.00 | ||
Although it is primarily a CDK4/6 inhibitor, there might be some interaction with CDK8. It leads to cell cycle arrest in the G1 phase. | ||||||